Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Table 2

Chemotherapy response.

	All patients ()		Belotecan ()		Topotecan ()
	Number	%	Number	%	Number	%
Complete response	2/66	3.0	2/46	4.3	0	0
Partial response	9/66	13.6	8/46	17.4	1/20	5
Stable disease	26/66	26.3	19/46	41.3	7/20	35
Progressive disease	29/66	43.9	17/46	37	12/20	60
Not evaluated	28/94	29.8	13/59	22	15/35	42.9
Response rate	11/66	16.7	10/46	21.7	1/20	5

Response rate = complete response + partial response.